Bristol Myers Squibb (BMS; NYSE: BMY) has announced the release of long-term clinical data for Sotyktu (deucravacitinib), the company’s tyrosine kinase 2 (TYK2) inhibitor, used in the treatment of moderate-to-severe plaque psoriasis. The data, which spans a four-year period, indicates that the first-in-class drug has maintained a clinical response rate of 71.7%. Notably, 57.2% of the participants in the trial achieved clear or almost clear skin.
The extended trial results also confirmed the absence of new safety signals, reinforcing the drug’s potential to become an oral standard of care for plaque psoriasis.- Flcube.com
